Shares of DaVita HealthCare Partners Inc. (NYSE:DVA) have been assigned an average rating of “Hold” from the thirteen research firms that are covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, eight have given a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $68.67.

Several analysts recently commented on the stock. BidaskClub downgraded shares of DaVita HealthCare Partners from a “sell” rating to a “strong sell” rating in a report on Saturday. Jefferies Group LLC downgraded shares of DaVita HealthCare Partners from a “buy” rating to a “hold” rating and lifted their target price for the stock from $64.89 to $70.00 in a report on Monday, June 26th. Zacks Investment Research downgraded shares of DaVita HealthCare Partners from a “hold” rating to a “sell” rating in a report on Tuesday, July 4th. Goldman Sachs Group, Inc. (The) reaffirmed a “sell” rating and set a $62.00 target price on shares of DaVita HealthCare Partners in a report on Thursday, May 25th. Finally, TheStreet cut shares of DaVita HealthCare Partners from a “b” rating to a “c+” rating in a research note on Wednesday.

ILLEGAL ACTIVITY WARNING: “DaVita HealthCare Partners Inc. (DVA) Given Consensus Recommendation of “Hold” by Brokerages” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://www.americanbankingnews.com/2017/08/05/davita-healthcare-partners-inc-dva-given-consensus-recommendation-of-hold-by-brokerages.html.

In other news, Director Charles Berg sold 8,414 shares of the business’s stock in a transaction that occurred on Tuesday, May 9th. The shares were sold at an average price of $65.80, for a total value of $553,641.20. Following the completion of the transaction, the director now directly owns 34,719 shares in the company, valued at approximately $2,284,510.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Javier Rodriguez sold 1,294 shares of the business’s stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $66.21, for a total transaction of $85,675.74. Following the completion of the transaction, the chief executive officer now owns 99,111 shares of the company’s stock, valued at $6,562,139.31. The disclosure for this sale can be found here. 2.10% of the stock is owned by insiders.

Several institutional investors have recently modified their holdings of DVA. Pzena Investment Management LLC boosted its position in shares of DaVita HealthCare Partners by 2.1% in the second quarter. Pzena Investment Management LLC now owns 3,398 shares of the company’s stock valued at $220,000 after buying an additional 71 shares during the last quarter. Eqis Capital Management Inc. boosted its position in shares of DaVita HealthCare Partners by 2.2% in the second quarter. Eqis Capital Management Inc. now owns 4,600 shares of the company’s stock valued at $298,000 after buying an additional 100 shares during the last quarter. Pacer Advisors Inc. boosted its position in shares of DaVita HealthCare Partners by 3.0% in the first quarter. Pacer Advisors Inc. now owns 3,422 shares of the company’s stock valued at $233,000 after buying an additional 101 shares during the last quarter. Wetherby Asset Management Inc. boosted its position in shares of DaVita HealthCare Partners by 3.3% in the first quarter. Wetherby Asset Management Inc. now owns 3,224 shares of the company’s stock valued at $219,000 after buying an additional 104 shares during the last quarter. Finally, SRS Capital Advisors Inc. boosted its position in shares of DaVita HealthCare Partners by 6.6% in the first quarter. SRS Capital Advisors Inc. now owns 1,966 shares of the company’s stock valued at $133,000 after buying an additional 122 shares during the last quarter. Institutional investors own 82.90% of the company’s stock.

Shares of DaVita HealthCare Partners (DVA) traded down 1.37% on Friday, hitting $57.70. 1,669,657 shares of the stock were exchanged. The company has a 50-day moving average price of $64.78 and a 200-day moving average price of $66.07. The firm has a market capitalization of $11.03 billion, a PE ratio of 8.79 and a beta of 0.89. DaVita HealthCare Partners has a one year low of $54.50 and a one year high of $76.97.

DaVita HealthCare Partners (NYSE:DVA) last announced its earnings results on Tuesday, August 1st. The company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.90 by $0.02. The business had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.82 billion. DaVita HealthCare Partners had a net margin of 8.68% and a return on equity of 14.02%. DaVita HealthCare Partners’s revenue was up 4.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.01 EPS. Equities research analysts expect that DaVita HealthCare Partners will post $3.54 earnings per share for the current year.

DaVita HealthCare Partners Company Profile

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Analyst Recommendations for DaVita HealthCare Partners (NYSE:DVA)

Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.